{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:42:40Z","timestamp":1753274560970,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10388-024-01067-7","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:00:50Z","timestamp":1717059650000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of definitive carbon-ion radiotherapy for cT1bN0M0 esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-5027","authenticated-orcid":false,"given":"Tetsuro","family":"Isozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nabeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisahiro","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2307\/3579446","volume":"147","author":"T Kanai","year":"1997","unstructured":"Kanai T, Furusawa Y, Fukutsu K, et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res. 1997;147:78\u201385.","journal-title":"Radiat Res"},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1269\/jrr.46.51","volume":"46","author":"K Ando","year":"2005","unstructured":"Ando K, Koike S, Uzawa A, et al. Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res. 2005;46:51\u20137.","journal-title":"J Radiat Res"},{"key":"1067_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.adro.2018.09.004","volume":"4","author":"DM Routman","year":"2019","unstructured":"Routman DM, Garant A, Lester SC, et al. A comparison of Grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. Adv Radiat Oncol. 2019;4:63\u20139.","journal-title":"Adv Radiat Oncol"},{"key":"1067_CR4","first-page":"1045","volume":"62","author":"T Sumiya","year":"2021","unstructured":"Sumiya T, Ishikawa H, Hiroshima Y, et al. The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients. J Radiat Res. 2021;62:1045\u201355.","journal-title":"J Radiat Res"},{"key":"1067_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2020.12.019","volume":"156","author":"N Kim","year":"2021","unstructured":"Kim N, Myoung Noh J, Lee W, et al. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy. Radiother Oncol. 2021;156:166\u201373.","journal-title":"Radiother Oncol"},{"key":"1067_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","volume":"118","author":"X Wang","year":"2023","unstructured":"Wang X, van Rossum PSN, Chu Y, et al. Severe lymphopenia during chemoradiation therapy for esophageal cancer: comprehensive analysis of randomized Phase 2B Trial of proton beam therapy versus intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2023;118:368\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jjco\/hys104","volume":"42","author":"H Tsujii","year":"2012","unstructured":"Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42:670\u201385.","journal-title":"Jpn J Clin Oncol"},{"key":"1067_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijrobp.2023.04.014","volume":"117","author":"T Isozaki","year":"2023","unstructured":"Isozaki T, Ishikawa H, Yasuda S, et al. A phase I\/II trial of definitive carbon ion radiotherapy for clinical T1bN0M0 esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2023;117:416\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf). Accessed 2024.02.08"},{"key":"1067_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2005.09.043","volume":"64","author":"T Kanai","year":"2006","unstructured":"Kanai T, Matsufuji N, Miyamoto T, et al. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys. 2006;64:650\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1\u201336.","journal-title":"Esophagus"},{"key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1053\/j.gastro.2021.08.007","volume":"161","author":"K Kato","year":"2021","unstructured":"Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161:1878-86.e2.","journal-title":"Gastroenterology"},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/cancers11070993","volume":"11","author":"T Ono","year":"2019","unstructured":"Ono T, Wada H, Ishikawa H, et al. Clinical results of proton beam therapy for esophageal cancer: multicenter retrospective study in Japan. Cancers (Basel). 2019;11:993.","journal-title":"Cancers (Basel)"},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.21873\/invivo.12277","volume":"35","author":"Y Takakusagi","year":"2021","unstructured":"Takakusagi Y, Yoshida D, Kusano Y, et al. Dosimetric comparison between carbon-ion radiotherapy and photon radiotherapy for stage I esophageal cancer. In Vivo. 2021;35:447\u201352.","journal-title":"In Vivo"},{"key":"1067_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijrobp.2013.04.006","volume":"86","author":"J Wang","year":"2013","unstructured":"Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86:885\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR16","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/jrr\/rrad012","volume":"64","author":"S Tokumaru","year":"2023","unstructured":"Tokumaru S, Ishikawa H, Soejima T, et al. Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer. J Radiat Res. 2023;64:i16\u201324.","journal-title":"J Radiat Res"},{"key":"1067_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/cas.12764","volume":"106","author":"M Tahara","year":"2015","unstructured":"Tahara M, Fuse N, Mizusawa J, et al. Phase I\/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II\/III esophageal carcinoma (JCOG 0604). Cancer Sci. 2015;106:1414\u201320.","journal-title":"Cancer Sci"},{"key":"1067_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","volume":"114","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 2022;114:454\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10147-015-0819-2","volume":"20","author":"Y Murakami","year":"2015","unstructured":"Murakami Y, Takahashi I, Nishibuchi I, et al. Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0). Int J Clin Oncol. 2015;20:897\u2013904.","journal-title":"Int J Clin Oncol"},{"key":"1067_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2307\/3577549","volume":"123","author":"N Nakamura","year":"1990","unstructured":"Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123:224\u20137.","journal-title":"Radiat Res"},{"key":"1067_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67:65\u201385.","journal-title":"CA Cancer J Clin"},{"key":"1067_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijrobp.2020.04.023","volume":"108","author":"JC Jagodinsky","year":"2020","unstructured":"Jagodinsky JC, Harari PM, Morris ZS. The promise of combining radiation therapy with immunotherapy. Int J Radiat Oncol Biol Phys. 2020;108:6\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1067_CR23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/fon-2020-0969","volume":"17","author":"MA Shah","year":"2021","unstructured":"Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021;17:1143\u201353.","journal-title":"Future Oncol"},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.2217\/fon-2021-0632","volume":"17","author":"R Yu","year":"2021","unstructured":"Yu R, Wang W, Li T, et al. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol. 2021;17:4081\u20139.","journal-title":"Future Oncol"},{"key":"1067_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059779","volume":"12","author":"S Ogasawara","year":"2022","unstructured":"Ogasawara S, Koroki K, Makishima H, et al. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open. 2022;12: e059779.","journal-title":"BMJ Open"},{"key":"1067_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056424","volume":"12","author":"N Okonogi","year":"2022","unstructured":"Okonogi N, Usui H, Murata K, et al. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study. BMJ Open. 2022;12: e056424.","journal-title":"BMJ Open"},{"key":"1067_CR27","doi-asserted-by":"publisher","first-page":"10565","DOI":"10.3390\/ijms241310565","volume":"24","author":"N Okonogi","year":"2023","unstructured":"Okonogi N, Murata K, Yamada S, et al. A Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION Study): the early safety and efficacy results. Int J Mol Sci. 2023;24:10565.","journal-title":"Int J Mol Sci"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-024-01067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-024-01067-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-024-01067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:17:40Z","timestamp":1726661860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-024-01067-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s10388-024-01067-7","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"type":"print","value":"1612-9059"},{"type":"electronic","value":"1612-9067"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statement and informed consent"}}]}}